Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since its 2022 spin-off from BD. That includes an FDA approval for a disposable insulin patch pump system in September 2024, only to be followed by the discontinuation […]
embecta
Embecta to undergo further restructuring, lowers guidance amid tariff impact
Embecta (Nasdaq:EMBC) stock was down today after news of restructuring and mixed second-quarter results. Shares of EMBC were down more than 8% to $12.12 apiece near the close of trading today. While the company continues to work through the discontinuation of its insulin patch pump program — the plan for which it says is substantially […]
Embecta shares study highlighting need for training, standardization in insulin delivery
Embecta (Nasdaq:EMBC) announced a new publication introducing best practices for insulin injection techniques and education. The publication in the Mayo Clinic Proceedings introduces the FITTER Forward Expert Recommendations. These best practices, authored by a panel of 16 diabetes specialists from 13 countries, highlight the critical need for improved training and standardization in insulin delivery. It […]
Embecta stock rises on Street-beating Q1, patch pump continuation remains on track
Embecta (Nasdaq:EMBC) shares ticked up before hours today on first-quarter results that came in ahead of the consensus forecast. Shares of EMBC rose 1.65% to $18.50 apiece in pre-market trading today. The Parsippany, New Jersey-based diabetes technology company reported profits of $157.1 million. That equals $0 per share on sales of $261.9 million for the […]
Analysts say Embecta is ‘heading in the right direction’ following patch pump discontinuation
Analysts called a recent stock sell-off at Embecta (Nasdaq:EMBC) “unwarranted” and believe the company is moving in the right direction despite recent challenges. Late last year, Embecta filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. This related to the company’s plans to discontinue its insulin patch pump program and restructure. […]
Embecta to lay off 118 in Massachusetts following patch pump program discontinuation
Embecta (Nasdaq:EMBC) filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees. The state received Embecta’s Worker Adjustment and Retraining Notification (WARN) submission on Nov. 26 — the same day it announced plans to discontinue its insulin patch pump program and restructure. The discontinuation of the patch pump program came not […]
Embecta discontinues insulin patch pump program, plans restructuring
Embecta (Nasdaq:EMBC) announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan. Shares of EMBC ticked up 4.3% to $14.41 apiece before hours after the company announced the discontinuation as part of its fourth-quarter earnings results. The BD Diabetes spinoff won FDA approval for a disposable patch pump system […]
The biggest diabetes tech stories of the year so far
On World Diabetes Day, it’s worth taking a look back at the last 10.5 months in the diabetes technology space. The date, which marks the birth date of the inventor of insulin, brings out all sorts of initiatives from various companies involved in innovating these technologies (read about those HERE). Those companies have contributed to […]
What diabetes tech companies are doing on World Diabetes Day 2024
World Diabetes Day — today, Nov. 14 — brings out the best in the diabetes community that continues to innovate year after year. This date serves as a time to recognize these innovations as it marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. The […]
Embecta wins FDA clearance for disposable insulin patch pump
Embecta (Nasdaq:EMBC) announced today that it received FDA 510(k) clearance for its proprietary disposable insulin delivery system. The open-loop system is indicated for adults who require insulin to manage diabetes, including both type 1 and type 2 diabetes. It features a tubeless design with a 300-unit insulin reservoir, informed by feedback from people with type […]
